全文获取类型
收费全文 | 2337篇 |
免费 | 107篇 |
国内免费 | 283篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 80篇 |
妇产科学 | 24篇 |
基础医学 | 264篇 |
口腔科学 | 12篇 |
临床医学 | 131篇 |
内科学 | 1064篇 |
皮肤病学 | 32篇 |
神经病学 | 11篇 |
特种医学 | 67篇 |
外科学 | 404篇 |
综合类 | 279篇 |
预防医学 | 71篇 |
眼科学 | 18篇 |
药学 | 114篇 |
中国医学 | 83篇 |
肿瘤学 | 61篇 |
出版年
2024年 | 1篇 |
2023年 | 55篇 |
2022年 | 82篇 |
2021年 | 114篇 |
2020年 | 103篇 |
2019年 | 129篇 |
2018年 | 113篇 |
2017年 | 87篇 |
2016年 | 77篇 |
2015年 | 98篇 |
2014年 | 188篇 |
2013年 | 176篇 |
2012年 | 143篇 |
2011年 | 153篇 |
2010年 | 124篇 |
2009年 | 158篇 |
2008年 | 141篇 |
2007年 | 124篇 |
2006年 | 112篇 |
2005年 | 107篇 |
2004年 | 70篇 |
2003年 | 57篇 |
2002年 | 47篇 |
2001年 | 42篇 |
2000年 | 32篇 |
1999年 | 35篇 |
1998年 | 25篇 |
1997年 | 20篇 |
1996年 | 21篇 |
1995年 | 19篇 |
1994年 | 11篇 |
1993年 | 9篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有2727条查询结果,搜索用时 15 毫秒
1.
《Journal of cystic fibrosis》2022,21(6):908-921
This paper is the first in a series providing updated guidance on the definition, evaluation and management of people with a Cystic Fibrosis Transmembrane conductance Regulator (CFTR)-Related Disorder (CFTR-RD). The need for this update relates to more precise characterisation of CFTR gene variants and improved assessment of CFTR protein dysfunction. The exercise is co-ordinated by the European CF Society Standards of Care Committee and Diagnostic Network Working Group and involves stakeholder engagement. This first paper was produced by a core group using an extensive literature review and papers graded for their quality. Subsequent wider stakeholder agreement was achieved.The definition of a CFTR-RD remains “a clinical condition with evidence of CFTR protein dysfunction that does not fulfil the diagnostic criteria for CF”. Clearer guidance on CFTR dysfunction and relevant CFTR variants will be provided. Thresholds for clinical presentations are presented and the paradigm that pathobiological processes may be evident in more than one organ is agreed. In this paper we reflect on the early patient journey, highlighting that CF specialists as well as other relevant specialists should be involved in the care of people with a CFTR-RD. 相似文献
2.
Laura S. Gold Donald L. Patrick Ryan N. Hansen Christopher H. Goss Larry Kessler 《Journal of cystic fibrosis》2019,18(6):886-893
BackgroundPulmonary exacerbations (PEx) in cystic fibrosis (CF) patients reduce quality of life. Lung function, measured by the percent predicted forced expiratory volume in 1 s (ppFEV1), is widely used to evaluate PEx treatments. We analyzed the correspondence of ppFEV1 with 8 patient-reported symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).MethodsData were derived from the observational Standardized Treatment of Pulmonary Exacerbations (STOP) study. CF patients who had CFRSD-CRISS and ppFEV1 measurements on ≥2 timepoints were included: 1) day of initial PEx, 2) 7 days later, and/or 3) end of PEx. We calculated age-stratified Spearman correlation coefficients and 95% confidence intervals (95% CIs) between the change in ppFEV1 and change in CFRSD-CRISS items from index to day 7 and from index to the end of PEx treatment.ResultsLung function and symptom scores improved by the end of treatment; however, correlations between ppFEV1 and the specific CFRSD-CRISS measures were mostly weak to moderate. An exception was that among patients <18, we observed moderately strong correlations between changes in ppFEV1 and cough severity (r = ?0.58 (95% CI: ?0.80, ?0.21)), mucus quantity (r = ?0.51 (?0.77, ?0.11)), and wheezing (r = ?0.53 (?0.78, ?0.14)) from index until end of treatment.ConclusionsAs novel treatments are developed for PEx, it is important to ensure that improvement is measured meaningfully. The generally weak associations between patient-reported symptoms and ppFEV1 that we found suggest that these measures capture different aspects of the disease and both metrics are important when evaluating new treatments. 相似文献
3.
Ageing is a multifactorial biological process leading to a progressive decline of physiological functions. The process of ageing includes numerous changes in the cells and the interactions between cell-cell and cell-microenvironment remaining as a critical risk factor for the development of chronic degenerative diseases. Systemic inflammation, known as inflammageing, increases as a consequence of ageing contributing to age-related morbidities. But also, persistent and uncontrolled activation of fibrotic pathways, with excessive accumulation of extracellular matrix (ECM) and organ dysfunction is markedly more frequent in the elderly. In this context, we introduce here the concept of Fibroageing, that is, the propensity to develop tissue fibrosis associated with ageing, and propose that ECM is a key player underlying this process. During ageing, molecules of the ECM become damaged through many modifications including glycation, crosslinking, and accumulation, leading to matrix stiffness which intensifies ageing-associated alterations. We provide a framework with some mechanistic hypotheses proposing that stiff ECM, in addition to the well-known activation of fibrotic positive feedback loops, affect several of the hallmarks of ageing, such as cell senescence and mitochondrial dysfunction, and in this context, is a key mechanism and a driver thread of Fibroageing. 相似文献
4.
5.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献6.
7.
8.
9.
Newborn screening (NBS) for cystic fibrosis (CF) was implemented throughout France since 2002, with a 3-tiered strategy consisting in an immunoreactive trypsinogen (IRT) measurement at day-3, a search for the most common mutations responsible for CF when the IRT value is above the cut-off level, and, if necessary, a safetynet retesting of IRT at day-21. Coordination and follow-up are ensured at the national level and NBS is carried out through a regional organization involving NBS centers, biochemical and molecular genetics laboratories. Sweat testing and comprehensive mutation gene analysis are then performed according to a defined algorithm. Between 2002 and 2014, screening for the 30 most common mutations identified 87% of the alleles and comprehensive mutation gene analysis performed when applicable identified more than 300 additional mutations and resulted in a detection rate of 99.8% of the mutated alleles. Program surveillance ensured at a national level allowed to carry out adaptation of cut-off levels and removal of the p.Arg117His mutation. Thanks to these modifications, the performance of the French NBS program for CF meets the European guideline standards regarding positive predictive values, sensitivity and time to initial visit at the CF center, thus making the strategy effective.© 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved. 相似文献
10.
子宫腺肌病(ADS)是子宫内膜腺体及间质侵入子宫肌层导致的以子宫局灶或弥漫性增大为主要改变的良性疾病,其具体发病机制尚不清楚。目前多数研究者认为ADS是基底层内膜细胞增生、侵入到肌层间质的结果。在上皮-间质转化(EMT)过程中,上皮细胞失去细胞极性,细胞间紧密连接和黏附连接减弱,获得了浸润性和游走迁移能力,成为具有间质细胞功能和特性的细胞。EMT在肿瘤形成中赋予细胞迁移、浸润的能力,而ADS发生、发展过程中子宫内膜细胞侵入肌层的生物学行为与之非常相似。已有研究表明EMT在ADS形成中具有重要作用。目前ADS的临床治疗面临较多的挑战,因此阐明ADS的发生机制是寻求临床早期预防、治疗ADS有效方法的关键。 相似文献